GSK-3 as potential target for therapeutic intervention in cancer

Giuseppe Montalto, Melchiorre Cervello, Alberto M. Martelli, Melissa Sokolosky, Ferdinando Nicoletti, Nicole M. Davis, Steve L. Abrams, Jorg Basecke, Agnieszka Gizak, Zoya Demidenko, Dariusz Rakus, Antonino B. D'Assoro, Massimo Libra, Linda S. Steelman, Roberta Maestro, James A. Mccubrey, Lucio Cocco, Fred E. Bertrand, Steve L. Abrams

Risultato della ricerca: Article

275 Citazioni (Scopus)

Abstract

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.
Lingua originaleEnglish
pagine (da-a)2881-2911
Numero di pagine31
RivistaOncotarget
Volume5
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Entra nei temi di ricerca di 'GSK-3 as potential target for therapeutic intervention in cancer'. Insieme formano una fingerprint unica.

  • Cita questo

    Montalto, G., Cervello, M., Martelli, A. M., Sokolosky, M., Nicoletti, F., Davis, N. M., Abrams, S. L., Basecke, J., Gizak, A., Demidenko, Z., Rakus, D., D'Assoro, A. B., Libra, M., Steelman, L. S., Maestro, R., Mccubrey, J. A., Cocco, L., Bertrand, F. E., & Abrams, S. L. (2014). GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget, 5, 2881-2911.